Venrock Healthcare Capital Partners III, L.P. 13D and 13G filings for 4D Molecular Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-05-15 5:44 pm Sale | 2025-03-31 | 13G | 4D Molecular Therapeutics, Inc. FDMT | Venrock Healthcare Capital Partners III, L.P. | 677,600 1.500% | -2,274,771 (-77.05%) | Filing |
| 2025-02-14 6:09 pm Sale | 2024-12-31 | 13G | 4D Molecular Therapeutics, Inc. FDMT | Venrock Healthcare Capital Partners III, L.P. | 2,952,371 6.400% | -1,447,629 (-32.90%) | Filing |
| 2024-02-14 8:51 pm Purchase | 2023-12-31 | 13G | 4D Molecular Therapeutics, Inc. FDMT | Venrock Healthcare Capital Partners III, L.P. | 4,400,000 8.900% | 1,512,483 (+52.38%) | Filing |
| 2023-05-15 4:17 pm Purchase | 2023-05-05 | 13G | 4D Molecular Therapeutics, Inc. FDMT | Venrock Healthcare Capital Partners III, L.P. | 2,887,517 8.700% | 2,887,517 (New Position) | Filing |